Ekinci DY, et al. - Researchers conducted the study for comparing the effectiveness of 0.4 mg/0.01 ml (“low dose”) and 1 mg/0.025 ml (“standard dose”) intravitreal aflibercept (IVA) in the treatment of retinopathy of prematurity (ROP). The medical records of patients treated with the lower dose (low-dose group) or the more commonly used dose (standard-dose group) of IVA for type 1 or aggressive posterior retinopathy of prematurity (AP-ROP) have been assessed retrospectively. In total, 32 eyes of 16 patients in the low-dose group and 42 eyes of 21 patients in the standard-dose group were involved. Only the low-dose group had eyes that did not respond, despite the fact that the difference between groups was not statistically significant.